Ashton Thomas Private Wealth LLC Buys 7,930 Shares of Medtronic PLC $MDT

Ashton Thomas Private Wealth LLC increased its stake in shares of Medtronic PLC (NYSE:MDT) by 31.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 33,364 shares of the medical technology company’s stock after purchasing an additional 7,930 shares during the quarter. Ashton Thomas Private Wealth LLC’s holdings in Medtronic were worth $3,200,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. AXQ Capital LP grew its holdings in shares of Medtronic by 25.6% during the second quarter. AXQ Capital LP now owns 9,890 shares of the medical technology company’s stock worth $862,000 after buying an additional 2,013 shares in the last quarter. UMB Bank n.a. raised its holdings in shares of Medtronic by 65.8% in the third quarter. UMB Bank n.a. now owns 138,278 shares of the medical technology company’s stock valued at $13,170,000 after purchasing an additional 54,898 shares during the last quarter. Principal Financial Group Inc. lifted its position in shares of Medtronic by 17.2% in the third quarter. Principal Financial Group Inc. now owns 1,656,155 shares of the medical technology company’s stock worth $157,732,000 after purchasing an additional 242,910 shares in the last quarter. Sector Gamma AS lifted its position in shares of Medtronic by 35.5% in the third quarter. Sector Gamma AS now owns 303,441 shares of the medical technology company’s stock worth $28,900,000 after purchasing an additional 79,441 shares in the last quarter. Finally, Verdence Capital Advisors LLC boosted its holdings in Medtronic by 22.0% during the second quarter. Verdence Capital Advisors LLC now owns 29,396 shares of the medical technology company’s stock worth $2,562,000 after purchasing an additional 5,296 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.

Medtronic Trading Up 1.1%

Shares of Medtronic stock opened at $102.92 on Friday. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80. The business has a fifty day simple moving average of $99.44 and a two-hundred day simple moving average of $96.01. Medtronic PLC has a 1 year low of $79.55 and a 1 year high of $106.33. The company has a market capitalization of $131.95 billion, a price-to-earnings ratio of 27.74, a P/E/G ratio of 2.68 and a beta of 0.71.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The business had revenue of $8.96 billion during the quarter, compared to the consensus estimate of $8.86 billion. During the same quarter in the previous year, the firm posted $1.26 EPS. Medtronic’s revenue was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Research analysts forecast that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, January 16th. Stockholders of record on Friday, December 26th were given a $0.71 dividend. The ex-dividend date of this dividend was Friday, December 26th. This represents a $2.84 annualized dividend and a dividend yield of 2.8%. Medtronic’s dividend payout ratio is presently 76.55%.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Analysts remain constructive — several outlets highlight bullish analyst views on Medtronic, supporting confidence in longer‑term growth prospects. Analysts Are Bullish on These Healthcare Stocks: Medtronic (MDT)
• Positive Sentiment: Product/market expansion — coverage notes Medtronic is broadening its heart and diabetes tools and integrating new offerings, which can support revenue growth and investors’ valuation assumptions. Medtronic Expands Heart And Diabetes Tools As Valuation Nears Analyst Views
• Positive Sentiment: Strategic M&A — Medtronic expanded its cath lab portfolio with the CathWorks acquisition, strengthening structural/cath lab offerings and cross‑sell opportunities. That helps offset competitive pressure in some device categories. Medtronic expands cath lab portfolio with CathWorks acquisition
• Neutral Sentiment: New analyst coverage — Citigroup began coverage of MDT, which can increase analyst attention and trading liquidity; the ultimate impact depends on the published rating and target. Citigroup Begins Coverage on Medtronic (NYSE:MDT)
• Neutral Sentiment: Valuation and investor commentary are mixed — several pieces debate whether recent gains leave MDT reasonably priced; these discussions can moderate momentum but don’t directly change fundamentals. Is Medtronic (MDT) Still Reasonably Priced After Recent Share Price Gains?
• Neutral Sentiment: Leadership change — the president of Structural Heart, Nina Goodheart, is retiring; this is notable for execution risk in that business but not an immediate financial shock. Medtronic Structural Heart President Nina Goodheart to retire
• Neutral Sentiment: Market performance context — one note shows MDT outperformed intraday but underperformed peers on the day, signaling relative-strength questions even amid gains. Medtronic PLC stock underperforms Thursday when compared to competitors despite daily gains
• Negative Sentiment: Major legal setback — a U.S. jury found Medtronic unlawfully monopolized the market for certain vessel‑sealing devices and ordered roughly $382 million in damages to Applied Medical; this is the most immediate negative catalyst and creates financial, reputational and potentially precedent risks. Medtronic owes $382 million to medical device rival in antitrust lawsuit, US jury says Applied Medical Prevails in Antitrust Jury Trial Against Medtronic

Wall Street Analyst Weigh In

Several brokerages have commented on MDT. The Goldman Sachs Group set a $111.00 price target on shares of Medtronic and gave the stock a “neutral” rating in a research report on Wednesday, November 19th. Barclays increased their price target on Medtronic from $111.00 to $116.00 and gave the company an “overweight” rating in a research report on Thursday, January 8th. CICC Research initiated coverage on Medtronic in a research note on Friday, January 30th. They set an “outperform” rating on the stock. Robert W. Baird set a $103.00 target price on shares of Medtronic in a research note on Tuesday, December 16th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Medtronic in a research report on Monday, December 29th. Fifteen investment analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $110.67.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).